Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: A systematic review

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 273-279

  Jang, Sekwon ^a   Chae, Young Kwang ^a,b   Haddad, Tufia ^a   Majhail, Navneet S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Conflict of interest; Economic analysis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CLINICAL TRIAL; CONFLICT OF INTEREST; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG INDUSTRY; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; FISHER EXACT TEST; HUMAN; INFORMATION PROCESSING; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMATIC ERROR; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS, MEDICAL; FEMALE; HUMANS; RESEARCH SUPPORT AS TOPIC;

EID: 77953024444     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0870-7     Document Type: Review

References (46)

1. Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767
2. Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
3. Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. The Exemestane Study Group. J Clin Oncol 18: 1399-1411
4. Budzar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma. Cancer 79: 730-739
5. Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new aromatase inhibitor for advanced breast cancer: double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461
6. Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination.) trial efficacy and safety update analyses. Cancer 98: 1802-1810 (Pubitemid 37310221)
7. Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757 (Pubitemid 43016814)
8. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092 (Pubitemid 38298988)
9. Goss PE, Ingle JN, Martino S et al (2007) Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor. J Clin Oncol 25: 2006-2011
10. Eisen A, Trudeau M, Shelly W et al. (2009) The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: guideline recommendations. Cancer Care Ont. http://www.cancercare.on.ca/pdf/ pebc1-18f.pdf. Accessed 13 Oct 2009
11. Annemans L (2008) Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modeling to aid decision making. Pharmacoeconomics 26: 409-423
12. Clement FM, Harris A, Li JJ et al (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443
13. Friedberg M, Saffran B, Stinson TJ et al (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282: 1453-1457 (Pubitemid 29493799)
14. Krimsky S (1999) Conflict of interest and cost-effectiveness analysis. JAMA 282: 1474-1475
15. Thomas RK, Williams M, Glen J et al (2009) Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer. Breast Cancer Res Treat 117(2): 289-295
16. Locker GY, Mansel R, Cella D et al (2007) Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 106(2): 229-238
17. Mansel R, Locker G, Fallowfield L et al (2007) Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. Br J Cancer 97: 152-161 (Pubitemid 47057463)
18. Rocchi A, Verma S (2006) Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 14: 917-927
19. Lundkvist J, Wilking N, Holmberg S et al (2007) Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 102: 289-299 (Pubitemid 46474838)
20. Risebrough NA, Verma S, Trudeau M et al (2007) Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer 110: 499-508 (Pubitemid 47106137)
21. Thompson D, Taylor DC, Montoya EL et al (2007) Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 10: 367-376 (Pubitemid 47485660)
22. Delea TE, El-Ouagari K, Karnon J et al (2008) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 108: 375-387 (Pubitemid 351431071)
23. Delea TE, Karnon J, Sofrygin O et al (2007) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 7: 608-618 (Pubitemid 47025818)
24. El Ouagari K, Karnon J, Delea T et al (2007) Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 101: 37-49 (Pubitemid 47555323)
25. Karnon J, Delea T, Johnston SR et al (2006) Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 24: 237-250 (Pubitemid 43374376)
26. Delea TE, Karnon J, Smith RE et al (2006) Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 12: 374-386 (Pubitemid 44063449)
27. Karnon J, Delea T, Barghout V (2008) Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 9: 171-183
28. Skedgel C, Rayson D, Dewar R et al (2007) Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifenexemestane and extended tamoxifen-letrozole. Breast 16: 252-261 (Pubitemid 46796849)
29. Gil JM, Rubio-Terrés C, Del Castillo A et al (2006) Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transi Oncol 8: 339-348
30. Simons WR, Jones D, Buzdar A (2003) Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther 25: 2972-2987 (Pubitemid 37510604)
31. Lindgren P, Jönsson B, Redaelli A et al (2002) Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics 20: 101-108 (Pubitemid 34275759)
32. Hillner BE, Radice D (2001) Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91: 484-489
33. Karnon J, Jones T (2003) A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. Pharmacoeconomics 21: 513-525 (Pubitemid 36560700)
34. Karnon J, Johnston SR, Jones T et al (2003) A trial-based costeffectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann Oncol 14: 1629-1633 (Pubitemid 37455811)
35. Nuijten M, McCormick J, Waibel F et al (2000) Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value Health 3: 31-39 (Pubitemid 30232946)
36. Nuijten M, Meester L, Waibel F et al (1999) Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 16: 379-397 (Pubitemid 29496048)
37. Marchetti M, Caruggi M, Colombo G (2004) Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model, analysis of costs in the Italian National Health Service. Clin Ther 26: 1546-1561 (Pubitemid 39572164)
38. Verma S, Rocchi A (2003) Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer 11: 728-734 (Pubitemid 37432630)
39. Dranitsaris G, Verma S, Trudeau M (2003) Cost utility analysis of first-line hormonal therapy in. advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol 26: 289-296 (Pubitemid 36712646)
40. Dranitsaris G, Leung P, Mather J et al (2000) Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 11: 591-601
41. Hillner BE (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer, Cancer 101: 1311-1322
42. Skedgel C, Rayson D, Dewar R et al (2007) Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 101: 325-333 (Pubitemid 46169887)
43. Younis T, Rayson D, Dewar R et al (2007) Modeling for costeffective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol 18: 293-298 (Pubitemid 46323096)
44. Lønning PE (2006) Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer, Ann Oncol 17: 217-225
45. Piskur P, Sonc M, Cufer T et al (2006) Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. Anticancer Drugs 17: 719-724 (Pubitemid 44265873)
46. Moeremans K, Annemans L (2006) Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gynecol Cancer 16: 576-578 (Pubitemid 44410972)